PIPELINE
PIPELINE
NIT is currently conducting multiple clinical trials of NT-I7 as a monotherapy and in combination with leading immunotherapeutics such as checkpoint inhibitors and more.
In addition, NIT is relentlessly conducting proof-of-concept animal studies in additional indications to further strengthen our pipeline and broaden the proof of applicability of NT-I7.
NT-I7 (efineptakin alfa) Development Program
| Disease Area | Study | Indication / Combination | Pre-clinical | Phase 1 | Phase 1/2 | Phase 2 | Phase 3 | Collaborator | Link |
|---|---|---|---|---|---|---|---|---|---|
| ONCOLOGY | NIT-106 | High Risk Skin Cancers / TECENTRIQ |  |
 |
|||||
| NIT-110 | Solid Tumors1 / KEYTRUDA (KEYNOTE-A60) |  |
|
||||||
| GX-I7-CA-006 | TNBC / KEYTRUDA (KEYNOTE-899) 2 |  |
|
||||||
| NIT-109 | Gastric, GEJ, & EAC / OPDIVO |  |
|
||||||
| NIT-119 | NSCLC (1L) / TECENTRIQ | |
|
||||||
| NIT-112 | LBCL / KYMRIAH | |
|||||||
| NIT-104 | GBM (single dose) | |
|||||||
| NIT-107 | GBM (multi dose)3 |  |
|
||||||
| NIT-120 | GBM (Recurrence) / Keytruda3 |  |
|||||||
| NIT-115 | SCCHN3,4 |  |
|
||||||
| NIT-108 | Kaposi Sarcoma3 |  |
|
||||||
| IMMUNOLOGY & INFECTIOUS DISEASES |
NIT-116 | COVID-19 |   |
|
|||||
| NIT-105 | Vaccine Adjuvant: Elderly Cancer Survivors 3 |  |
|
||||||
| NIT-113 | Progressive Multifocal Leukoencephalopathy 3,5 |  |
|
||||||
| NIT-114 | Idiopathic CD4 Lymphocytopenia 3,6 | |
|||||||
| OTHER | N/A | Acute Radiation Syndrome | |||||||
|
1. TNBC, NSCLC, SCLC, PaC, MSS-CRC 2. Genexine sponsored; NIT co-funds under 3-way agreement with Merck 3. Investigator-initiated trial 4. Squamous Cell Carcinoma of Head and Neck, Window-of-Opportunity 5. Orphan Drug Designation (US Jun 2020) 6. Orphan Drug Designation (EU May 2017 US Apr 2019) |
|||||||||
NeoImmuneTech provides this link as a courtesy and does not control the content of the site you are about to enter.
Do you wish to continue?